Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Table 3 Classification of subject IDs with valid re-read data

	Treatment group (randomized and received at least one dose)
	Placebo (N = 101)	TQ 200 mg (N = 104)	MQ 250 mg (N = 101)	Total (N = 306)
No. of subjects with valid re-read results	93	100	96	289
No. of subjects with positive smears	31	2	2	35
No. of subjects without positive smears	62	98	94	254
No. of subjects without valid re-read results	8	4	5	17

Valid re-read slides are those with either an outcome of “positive” or “negative” and were collected on or after the 1st dose

ISSN: 1475-2875